Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple oral dose study of WAL2014 (Talsaclidine) in healthy male volunteers
NCT02264080Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 1999
- Primary completion
- Mar 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing WAL2014 with Placebo (2 arms). Primary endpoints: Maximum concentration of the analyte in plasma, Time to reach maximum plasma concentration and 8 more. Started Mar 1999; status: completed.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02264080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264080.